Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis by Lorenzo Loffredo et al.
Loffredo et al. BMC Cardiovascular Disorders 2012, 12:107
http://www.biomedcentral.com/1471-2261/12/107RESEARCH ARTICLE Open AccessUpstream therapy with statin and recurrence of
atrial fibrillation after electrical cardioversion.
Review of the literature and meta-analysis
Lorenzo Loffredo*, Francesco Angelico, Ludovica Perri and Francesco VioliAbstract
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia observed in clinical practice. Electrical
cardioversion (EC) is commonly used to restore and maintain sinus rhythm but it is characterized by high rate of
recurrences. Several trials analyzed the effects of statins to reduce the recurrences in AF with contradictory results.
Methods: We performed a meta-analysis of the interventional trials with statins in patients with persistent AF to
evaluate recurrences after EC. Only randomized controlled trials were included in the analysis. Data sources
included: Medline, ISI Web of Science, SCOPUS and Cochrane database (up to June 2012). Data extraction was
performed by three authors. Study-specific odds ratios (ORs) were combined using fixed-effects model.
Results: Six studies with 515 patients were included in the analysis. Statins used in the selected trials were:
atorvastatin (at dosages ranging from 10 to 80 mg/day), pravastatin (40 mg/day) and rosuvastatin (20 mg/day). AF
recurrence after EC occurred in 108/258 (41.8%) of patients treated with statins and in 132/257 (51.3%) patients not
on treatment with statins. Compared with control, recurrences were significantly reduced with statin treatment
(O.R.: 0.662; 95% C.I., 0.45-0.96; p=0.03); statin treatment was associated with an absolute risk reduction of 0.095 and
a number needed to treat of 11.
Conclusions: This review suggests that statin therapy was significantly associated with a decreased risk of
recurrence in patients with persistent AF after EC.
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Atrial fibrillation (AF) is the most common sustained
arrhythmia observed in clinical practice with prevalence
increasing with age [1]. Patients with AF have about
5-fold increase of stroke risk, which is prevalently
dependent on thrombosis occurring in the left atrium or
left atrium appendage [2]. Restoration of sinus rhythm
in patients with AF is a strategy to prevent the cardio-
vascular and thromboembolic complications of this
arrhythmia [3].
Persistent AF is one presentation of the disease. AHA
guidelines defined persistent AF when the arrhythmia
sustains beyond 7 days [1] and usually terminates with* Correspondence: lorenzo.loffredo@uniroma1.it
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reproduction in any medium, provided the orpharmacological therapy or direct-current electrical car-
dioversion (EC) [1].
Sinus rhythm restoration in AF is not associated to re-
duction of thromboembolic complications and mortality
[4-6]. However, the maintenance of sinus rhythm, in
patients with AF, gives potential benefits such as the pre-
vention of electrical and structural remodeling of the
atria, improved haemodynamic function, amelioration of
symptoms, and improvement for quality life [7].
EC is commonly used, with antiarrhythmic drugs, to
restore and maintain sinus rhythm [1]. These therapies
are limited by low efficacy [8]; one week after successful
EC, about 25% of patients will experience a recurrence
of the disease [8]. Besides research efforts to improve
the efficacy of antiarrhythmic agents, there is a growing
interest to the "upstream" therapy of AF [9,10]. Potential
upstream therapies, which seek to inhibit the formationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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angiotensin-converting enzyme inhibitors. Statins pos-
sess anti-inflammatory and antioxidant effects which can
counteract inflammatory and oxidative stress pathways
which are believed to contribute to the pathogenesis of
AF [11,12].
The relationship between statin therapy and AF recur-
rence in patients with AF has been evaluated by several
meta-analyses, which provided, however, conflicting
results[13-16]. These meta-analyses, however, did not
specifically investigate if statins reduce recurrence in
patients with persistent AF undergoing EC as different
clinical settings associated with AF were included in the
meta-analyses. Therefore, the main objective of our
study was to systematically review and analyze the effect




Randomized clinical trials (RCTs) studying the effect of
statins on recurrence of AF. No language, publication
date, or publication status restrictions were imposed.
Types of participants
Patients of any age, with persistent AF treated with EC,
were considered. Patients were excluded from this re-
view if AF was treated with surgical interventions.
Types of outcome measures
The rationale of this review was to analyze the clinical
effectiveness of statins to reduce the recurrences after
EC in patients with persistent AF.
Because EC is unsuccessful at converting AF to sinus
rhythm in some patients we performed a per-protocol
analysis, including only the patients who restored to nor-
mal rhythm.
Information sources
The studies were identified by searching electronic data-
bases. This search was applied to Medline, ISI Web of
Science, SCOPUS and Cochrane database. The last
search was run on 9 June 2012. Reference lists of all
studies included in the present systematic review were
screened for potential additional eligible studies.
Search
Studies were identified by searching Medline, ISI Web of
Science, SCOPUS and Cochrane Database by crossing
each of the following keywords:
– statin
– recurrence
– atrial fibrillation– electrical cardioversion
– randomized controlled trials
Study selection
Two authors (L.L., L.P.) independently reviewed all selected
titles and abstracts. Studies were excluded if the title and/or
abstract was not appropriate for the aim of our review. Full
texts were subsequently obtained for eligible studies or
when the relevance of an article could not be excluded with
certainty. Disagreement was resolved by consensus and by
opinion of a third reviewer (F.V.), if necessary.
Studies not including a control group drawn from the
same population, animal studies, or trials that exclusively
reported other clinical outcomes were excluded. Case
reports, editorials, commentaries, letters, review articles,
guidelines or secondary prevention trials were also
excluded from the analysis.
Data extraction and quality assessment
For RCTs we planned quality assessment (Table 1) by
means of Jadad’s scale [17] which evaluates the following
three study characteristics: method of randomization,
method of blinding, and follow-up. To stratify RCTs, we
applied the following cut-offs: a total of five points
defined high quality studies; three and four points
defined medium quality studies; two or less points
defined low quality studies.
This review was conducted and reported according
to the PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analysis) Statement issued in
2009 [18].Statistical analysis
To evaluate the effect of statins on recurrence of AF
after EC, we allocated the results of each randomized
controlled trial as dichotomous frequency data. Odds
ratios (ORs) and 95% confidence intervals (CIs) were
calculated. These data were pooled using a fixed-effects
model (the Mantel–Haenszel method) [19]. Statistical
heterogeneity was evaluated using the I2 statistic, which
assesses the appropriateness of pooling the individual
study results [17]. The I2 value provides an estimate of
the amount of variance across studies due to heterogen-
eity rather than chance. I2 <30% indicates mild heterogen-
eity, 30–50% moderate, and >50% severe heterogeneity.
The software Comprehensive Meta Analysis (version
2.2.064, USA, 2011) supported the analysis.
Results
The search provided a total of 316 citations. Of these,
293 studies were discarded after reviewing the titles and
abstracts because it appeared that these papers clearly
did not meet the selection criteria (Figure 1).















































































































































B: 49/68 YES/YES - 46/46 4
H, hypertension; D, diabetes mellitus; S: smoking; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; B, beta blockers; C, calcium channel blockers; DG, Digitoxin; F, Flecainide; A, Amiodarone;
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and were included in this systematic review.
The study identification and selection progression is
summarized in Figure 1.
All studies were written in English. The 6 studies ran-
ged in size from 44 to 234 patients for a total of 568
patients (Table 1). Three out of the studies were low
quality studies according to Jadad's score (Table 1).
Clinical characteristics of the study populations are illu-
strated in the Table 1. All the trials included patients with
an average age >50 years (Table 1). Compared to females,
males were more frequently distributed in all trials (Table 1),
except one, ranging from 48 to 82% (mean: 70.8%) in statin
group and from 44 to 84% (mean: 65%) in control group.
Only two trials, conducted by Almroth et al. [21] and
Negi et al. [24], were double-blind and placebo-controlled
studies (Table 1).
Intervention treatment started from randomization
day to 3 weeks before EC (Table 1).
Left atrial diameter ranged from 41 to 47 mm (mean:
44.6 mm) in statin group and from 41 to 46 mm (mean:
43.2 mm) in control group (Table 1).
The rate of previous coronary heart disease (CHD)
was specified in four studies [20,21,24,25].
Statins used in the selected trials were: atorvastatin
(at dosages ranging from 10 to 80 mg/day), pravastatin
(40 mg/day) and rosuvastatin (20 mg/day) (Table 1).
The mean follow-up of the studies ranged from 30
days to 1 year (mean 3.7±4.1 months) (Table 1).Figure 1 Flow diagram of study selection.CHADS score [8] was reported only in one study [21].
Concomitant treatments and comorbidities are
reported in Table 1.
Total cholesterol in the treated groups lowered from
15% to 32% according to the different type and dosage
of statin (Table 1).
The rate of recurrences was different, according to the
follow-up and to the treatment, among the studies ran-
ging from as high as 66.6% (22/33 patients) to as low as
12.5% (3/24 patients) in statin groups and from as high
as 83.8% (26/31 patients) to as low as 13.6% (3/22
patients) in control groups (Table 1).
AF recurrence after EC occurred in 108/258 (41.8%) of
patients treated with statins and in 132/257 (51.3%) con-
trols. Statins significantly reduced the recurrences (O.R.:
0.662; 95% C.I., 0.45-0.96; p=0.03) (Figure 2) with an ab-
solute risk reduction (ARR) of 0.095 and a number
needed to treat (NNT) of 11. Heterogeneity across the
studies[26] was moderate (I2=50, p=0.062).
Discussion
This systematic review reports, for the first time, that
upstream therapy with statins may be useful for the pre-
vention of recurrence in patients with persistent AF who
had undergone successful EC.
Previous meta-analyses studied the relationship be-
tween statins and AF, with inconclusive results. However
they did not distinguish among the different types of AF
(e.g. paroxysmal) [13-16], since observational studies
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bypass grafting (CABG)[14,16], or patients undergone to
EC [14,15]. Thus, these meta-analyses did not specific-
ally address the question as to whether statin treatment
is able to reduce or prevent recurrences in patients with
persistent AF undergoing EC [13-16].
This issue may be clinically relevant as statins have
anti-inflammatory properties and inhibit specific path-
ways generating oxidative stress, which are believed to
trigger AF. Indeed, inflammation may interfere with the
electrophysiological and structural changes of AF [27].
The presence of systemic inflammation, as shown by
high serum levels of high-sensitivity C reactive protein
(CRP) and interleukins 6 and 8, has been associated with
AF [27]. Also, Dernellis et al. demonstrated that treat-
ment with atorvastatin (initiated at a minimum of 20
mg/day and increased to a maximum of 40 mg/day) low-
ered CRP levels coincidentally with reduced recurrence
in patients with paroxysmal AF [28]. Same results were
detected by Negi et al. in atorvastatin (80 mg/day)- trea-
ted persistent AF patients, who underwent EC [24]. Oxi-
dative stress plays also a pivotal role in inducing and
maintaining AF [27,29]. The nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase is considered
the most important cellular source of reactive oxygen
species (ROS) in humans [30,31]; this enzyme is sug-
gested to be implicated in functional changes of the atria
which may favor AF [30]. Indeed, studies in humans
have shown that myocytes from the right atrial append-
age produce a significant amount of ROS through activa-
tion of NOX2, the catalytic subunit of NADPH oxidase
[32]. Furthermore, NOX2 activation was observed in ex-
perimental models of AF [33] and in patients with post-
surgery paroxysmal AF while it was within normal range
in patients with permanent AF [33]. In accordance with
this finding a serum activity of NOX2 was up-regulated
only in patients with paroxysmal-persistent AF [34] andFigure 2 Effect of statins on recurrences of atrial fibrillation.low serum levels of vitamin E, a known antioxidant [35],
and associated with AF recurrence in patients who
underwent EC [12]. As statin therapy inhibits ROS gen-
eration via down-regulation of NOX2 [33,36] and in-
crease the serum levels of vitamin E [37], it would be
tempting to speculate that inhibition of NOX2-
generated ROS may hamper recurrence in patients with
paroxysmal/persistent AF undergoing EC.
Therefore, down-regulation of NOX2 and inhibition of
CRP may represent a plausible mechanism accounting
for the beneficial effects observed by statin treatment in
our meta-analysis. The analysis of six RCT demon-
strated, in fact, an AF recurrence rate of 51.3% in con-
trol group and of 41.8% in statin-treated group with a
relative risk reduction of 19%. The absolute risk reduc-
tion (9.5%) resulted in a number needed to treat of 11
patients with persistent AF.
This meta-analysis has the following limitations. Only
two studies are placebo-controlled [21], [24] and all the
remaining are open-label studies. The sample size of the
included studies is low, ranging from 44 to 222 patients.
The Jadad score, used to evaluate the quality of the
trials, is low (<3) in about 50% of the studies included in
the meta-analysis (Table 1). Furthermore, the female
gender was less frequent with an average of 30% in the
different studies. Finally, there is a great heterogeneity
for cholesterol levels before and after treatment, statin
type and dosage among the studies included in this ana-
lysis (Table 1).
Conclusions
The results of this meta-analysis are of potential interest
as they could represent a useful background to plan fu-
ture studies to test the hypothesis that upstream therapy
with statins may be beneficial to prevent AF recurrence
in patients with persistent AF who undergo successful
EC.
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